Sunday, 18 May 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 18 May 2025
News

PBS drug touts complete response

Posted 9 May 2025 AM

A Phase 2 study has generated more evidence in favour of using GSK’s Jemperli to treat mismatch repair-deficient (dMMR) cancers, with data suggesting it can trigger complete tumour clearance, particularly in rectal cancer.

Jemperli was first approved by the TGA in 2022 in combination with carboplatin and paclitaxel for adults with primary advanced or recurrent endometrial cancer.

To see the whole article, please login

Popular

Company in trouble with the FDA
June PBS listings ready to roll
Govt quietly funds Novartis drug
No crash despite patent cliff fall
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (12)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Devices (1)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home